Neurol. praxi. 2017;18(2):117-120 | DOI: 10.36290/neu.2017.130

Botulinum toxin type A for the migraine prophylactic treatment Botulinum toxin type A for the migraine prophylactic treatment

MUDr. Andrea Bártková, Ph.D.
Neurologická klinika LF UP a FN Olomouc

Chronic migraine (CM) is a neurological disease that remains underdiagnosed and difficult to treat. In the comparison with episodic

migraine, patients with CM show a higher degree conditional functional limitation, reduced work productivity and quality

of life. This personal and socioeconomic burden emphasizes the urgent need for adequate treatment. Although we commonly

use a wide range of oral preventatives in the clinical practice, currently the only the Food and Drug Administration (FDA) approved

treatment for CM prevention is onabotulinumtoxin A. In this review, we discuss history and present perspectives of this therapy.

Keywords: chronic migraine, preventative therapy, onabotulinumtoxin A

Received: August 7, 2018; Accepted: September 24, 2018; Prepublished online: September 24, 2018; Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bártková A. Botulinum toxin type A for the migraine prophylactic treatment Botulinum toxin type A for the migraine prophylactic treatment. Neurol. praxi. 2017;18(2):117-120. doi: 10.36290/neu.2017.130.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ashkenazi A. Botulinum toxin type A for chronic migraine. Curr Neurol Neurosci Rep 2010; 10: 140-146. Go to original source... Go to PubMed...
    2. Aurora SK, Dodick DW, Diener H-C, DeGryse RE, Turkel CC. Lipton RB, Silberstein SD. OnabotulinumtoxinA for chronic migraine:efficacy, safety, and tolerability in patiens who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand 2014; 129: 61-70. Go to original source... Go to PubMed...
    3. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793-803. Go to original source... Go to PubMed...
    4. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007; 47: 486-499. Go to original source...
    5. Binder WJ, Brin MF, Blitzer A, Achoenrock LD, Pogoda JM. Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000; 123: 669-676. Go to original source...
    6. Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008; 48: 210-220. Go to original source...
    7. Blumenfeld AM, Silberstein SD, Dodick DW. Method of injection of onabotulinumtoxina for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 2010; 50: 1406-1418. Go to original source...
    8. Cady R, Schreiber CP, Porter JA, eBlumenfeld AM, Farmer KU. A multi-center double-blind placebo pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 2011; 51: 21-32. Go to original source...
    9. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125-133. Go to original source... Go to PubMed...
    10. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 804-814. Go to original source... Go to PubMed...
    11. Diener HC, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, Brin MF. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014; 21(6): 851-859. Go to original source...
    12. Dodick DW, Mauskop A, Elkind AH, DeGryse RE, Brin MF, Silberstein SD. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications (a randomized, double-blind, placebo-controlled study). Headache 2005; 45: 315-324. Go to original source...
    13. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921-936. Go to original source...
    14. Durham PL, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004; 44: 35-44. Go to original source...
    15. Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW. Duration of migraine is a predictor for response to botulinum toxin type A. Headache 2005; 45: 308-314. Go to original source...
    16. Headache Classification Committee. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33(9): 629-808. Go to original source... Go to PubMed...
    17. Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-746. Go to original source... Go to PubMed...
    18. Hepp Z, Rosen NL, Gillard PG, Varon SF, Mathew N, Dodick DW. Comparative effectivenes of onabotulinumtoxinA versus oral migraine prophylactic medication on headache related resource utilization in the management of chronic migraine: Retrospective analysis of a US based insurance claim database. Cephalalgia 2016; 0(0): Epub ahead of print. Go to original source... Go to PubMed...
    19. Christie SN, Giammarco R, Gawel M, Mackie G, Gladstone J, Becker WJ. Botulinum toxin type A and acute drug costs in migraine with triptan overuse. Can J Neurol Sci 2010; 37: 588-594. Go to original source... Go to PubMed...
    20. Jackson LJ, Kuryiama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension type headaches in adults. A meta analysis. Jama 2012; 307(16): 1736-1745. Go to original source... Go to PubMed...
    21. Lanteri Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse. A systematic review. Cefalalgia 2011; 31: 837-850. Go to original source... Go to PubMed...
    22. Magalhaes E, Menezes D, Cardeal M, Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg 2010; 112: 463-466. Go to original source... Go to PubMed...
    23. Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011; 15(1): 70-78. Go to original source... Go to PubMed...
    24. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebocontrolled trial. Headache 2005; 45: 293-307. Go to original source... Go to PubMed...
    25. Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxinA (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache 2009; 49: 1466-1478. Go to original source... Go to PubMed...
    26. Mathew NT, Kailasam J, Meadors L. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 2008; 48: 194-200. Go to original source... Go to PubMed...
    27. Monakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, Reed M, Lipton RB. Economic burden of transformed migraine: Results from the American Migraine Prevalence and Prevention study (AMPP). Headache 2009; 49: 498-508. Go to original source... Go to PubMed...
    28. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010; 30(5): 599-609. Go to original source... Go to PubMed...
    29. Negro A, Curto M, Lionetto L, Crialesi D, Martelletti P. OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. SpringerPlus 2015; 4: 826. Go to original source... Go to PubMed...
    30. Pavone F, Lusietto S. Botulinum neurotoxin for pain management: insights from animal models. Toxins 2012; 2: 2890-2913. Go to original source... Go to PubMed...
    31. Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000; 59: 1403-1406. Go to original source... Go to PubMed...
    32. Oterino A, Ramo'n C, Pascual J. Experience with onabotulinumtoxin A (BOTOX) in chronic refractory migraine: focus on severe attacks. J Headache Pain 2011; 12: 235-238. Go to original source... Go to PubMed...
    33. Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, doubleblind, randomized, placebo-controlled, parallel group study. J Headache Pain 2011; 12: 427-433. Go to original source... Go to PubMed...
    34. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patiens who had acute headache medication overuse at baseline. J Neurol Sci. 2013; 331(1-2): 48-56. Go to original source... Go to PubMed...
    35. Silberstein SD, Stark SR, Lucas SM, Christie SN, DeGryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80: 1126-1137. Go to original source... Go to PubMed...
    36. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000; 38: 245-258. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.